EOLSEvolus, Inc.
Pharmaceutical Preparations
- Revenue
- $297M
- 12% YoY
- Operating margin
- -11.0%
- 15% YoY
- EBITDA
- −$25M
- 14% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $112M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $100M | $149M | $202M | $266M | $297M | 12% |
| Operating income | −$44M | −$65M | −$49M | −$34M | −$33M | 5.1% |
| Net income | −$47M | −$74M | −$62M | −$50M | −$52M | 2.4% |
| Operating cash flow | −$33M | −$85M | −$34M | −$18M | −$42M | 135% |
| Capex | $393K | $2M | $473K | $1M | $3M | 134% |
| Stock-based comp | $10M | $11M | $16M | $22M | $21M | 7.0% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | −$746K | 102 | 120 |
| FY2024 | $7M | $5M | 170 | 91 |
| FY2023 | $11M | $14M | 162 | 92 |
| FY2022 | $4M | $6M | 115 | 90 |